Robert Ralston

5.9k total citations · 3 hit papers
78 papers, 4.8k citations indexed

About

Robert Ralston is a scholar working on Molecular Biology, Hepatology and Epidemiology. According to data from OpenAlex, Robert Ralston has authored 78 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Molecular Biology, 29 papers in Hepatology and 21 papers in Epidemiology. Recurrent topics in Robert Ralston's work include Hepatitis C virus research (28 papers), Virus-based gene therapy research (19 papers) and Monoclonal and Polyclonal Antibodies Research (14 papers). Robert Ralston is often cited by papers focused on Hepatitis C virus research (28 papers), Virus-based gene therapy research (19 papers) and Monoclonal and Polyclonal Antibodies Research (14 papers). Robert Ralston collaborates with scholars based in United States, Germany and United Kingdom. Robert Ralston's co-authors include J. Michael Bishop, Michael Houghton, Darryll D. Dudley, Margaret James Koziel, Bruce D. Walker, Q L Choo, Kent Thudium, George Kuo, C. Kuo and Karin Berger and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

Robert Ralston

77 papers receiving 4.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Vaccination of chimpanzees against infection by thehepatitis C virus.

1994 468 citations Robert Ralston et al. profile →
Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis

1992 418 citations Margaret James Koziel, Darryll D. Dudley et al. The Journal of Immunology profile →
Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV

1993 255 citations Margaret James Koziel, Darryll D. Dudley et al. Journal of Virology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert Ralston United States	37	2.1k	1.9k	1.8k	823	655	78	4.8k
Andrew J. Syder United States	24	3.3k 1.6×	2.8k 1.5×	1.4k 0.8×	531 0.6×	215 0.3×	29	5.3k
Elisa Scarselli Italy	28	1.6k 0.8×	1.5k 0.8×	681 0.4×	387 0.5×	530 0.8×	73	3.2k
Chiaho Shih United States	42	1.4k 0.7×	2.0k 1.1×	2.9k 1.6×	874 1.1×	1.3k 2.0×	90	6.1k
Toshiaki Maruyama Japan	23	2.1k 1.0×	2.0k 1.1×	783 0.4×	163 0.2×	185 0.3×	62	3.9k
Óscar R. Burrone Italy	41	467 0.2×	659 0.4×	1.4k 0.8×	839 1.0×	565 0.9×	150	4.9k
Piero Pileri Italy	19	2.2k 1.1×	1.7k 0.9×	619 0.4×	123 0.1×	170 0.3×	29	3.7k
Patrick R. Romano United States	21	761 0.4×	830 0.4×	1.8k 1.1×	208 0.3×	262 0.4×	26	3.2k
James W. Tung United States	22	638 0.3×	646 0.3×	848 0.5×	129 0.2×	425 0.6×	28	3.1k
Hans Reiser United States	37	423 0.2×	803 0.4×	719 0.4×	321 0.4×	513 0.8×	62	4.1k
Kazuhiro Kakimi Japan	42	804 0.4×	1.2k 0.6×	997 0.6×	282 0.3×	2.3k 3.5×	160	5.6k

Countries citing papers authored by Robert Ralston

Since Specialization

Citations

This map shows the geographic impact of Robert Ralston's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Ralston with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Ralston more than expected).

Fields of papers citing papers by Robert Ralston

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Ralston. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Ralston. The network helps show where Robert Ralston may publish in the future.

Co-authorship network of co-authors of Robert Ralston

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Ralston. A scholar is included among the top collaborators of Robert Ralston based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Ralston. Robert Ralston is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Liu, Dandan, Andrew D. Huber, Eleftherios Michailidis, et al.. (2023). Mechanisms of Action of the Host-Targeting Agent Cyclosporin A and Direct-Acting Antiviral Agents against Hepatitis C Virus. Viruses. 15(4). 981–981. 1 indexed citations

Tumurbaatar, Batbayar, Irina Tikhanovich, Zhuan Li, et al.. (2013). Hepatitis C and Alcohol Exacerbate Liver Injury by Suppression of FOXO3. American Journal Of Pathology. 183(6). 1803–1814. 22 indexed citations

Barnard, Richard J. O., John A. Howe, Robert A. Ogert, et al.. (2013). Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies. Virology. 444(1-2). 329–336. 54 indexed citations

Brass, Clifford A., Richard J. O. Barnard, John A. Howe, et al.. (2011). 1194 SUSTAINED VIROLOGIC RESPONSE AND BOCEPREVIR RESISTANCE-ASSOCIATED VARIANTS OBSERVED IN PATIENTS INFECTED WITH HCV GENOTPYPE 1A/1B WHEN TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN. Journal of Hepatology. 54. S471–S472. 9 indexed citations

Vermehren, Johannes, S. Süsser, Christian M. Lange, et al.. (2011). Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa‐2b. Journal of Viral Hepatitis. 19(2). 120–127. 39 indexed citations

Kong, Rong, et al.. (2010). A peptide derived from hepatitis C virus E2 envelope protein inhibits a post-binding step in HCV entry. Antiviral Research. 86(2). 172–179. 22 indexed citations

Süsser, S., Christoph Welsch, Yalan Wang, et al.. (2009). Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus–infected patients†. Hepatology. 50(6). 1709–1718. 252 indexed citations

Buontempo, Peter, Lisa Wojcik, Robert A. Ogert, et al.. (2009). Quantifying the relationship between HIV-1 susceptibility to CCR5 antagonists and virus affinity for antagonist-occupied co-receptor. Virology. 395(2). 268–279. 4 indexed citations

Qiu, Ping, Stephanie Curry, Zhiyong Guo, et al.. (2009). Identification of HCV protease inhibitor resistance mutations by selection pressure-based method. Nucleic Acids Research. 37(10). e74–e74. 36 indexed citations

10.

Ogert, Robert A., Lisa Wojcik, Lei Ba, et al.. (2008). Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120. Virology. 373(2). 387–399. 72 indexed citations

11.

Tsai, Van, et al.. (2008). Complement Component C1q and Anti-hexon Antibody Mediate Adenovirus Infection of a CAR-Negative Cell Line. Viral Immunology. 21(4). 469–476. 6 indexed citations

12.

Smith, Jason G., Aurélia Cassany, Larry Gerace, Robert Ralston, & Glen R. Nemerow. (2008). Neutralizing Antibody Blocks Adenovirus Infection by Arresting Microtubule-Dependent Cytoplasmic Transport. Journal of Virology. 82(13). 6492–6500. 53 indexed citations

13.

Ralston, Robert, et al.. (2007). [793] COMBINATION OF TWO HEPATITIS C VIRUS INHIBITORS, SCH 503034 AND NM107, PROVIDES ENHANCED ANTI-REPLICON ACTIVITY AND SUPPRESSES EMERGENCE OF RESISTANT REPLICONS. Journal of Hepatology. 46. S298–S299. 3 indexed citations

14.

Howe, Anita Y. M., Robert Ralston, Robert A. Chase, et al.. (2007). [432] FAVORABLE CROSS-RESISTANCE PROFILE OF TWO NOVEL HEPATITIS C VIRUS INHIBITORS, SCH-503034 AND HCV-796, AND ENHANCED ANTI-REPLICON ACTIVITY MEDIATED BY THE COMBINED USE OF BOTH COMPOUNDS. Journal of Hepatology. 46. S165–S165. 5 indexed citations

15.

Danciger, Michael, et al.. (2007). Discovery of QTL That Modify rd3-Induced Retinal Degeneration in the Mouse Model; Several Are in Common With QTL Affecting Age-Related Retinal Degeneration. Investigative Ophthalmology & Visual Science. 48(13). 4633–4633. 1 indexed citations

16.

Rahman, Amena, Van Tsai, Shu Fen Wen, et al.. (2001). Specific Depletion of Human Anti-adenovirus Antibodies Facilitates Transduction in an in Vivo Model for Systemic Gene Therapy. Molecular Therapy. 3(5). 768–778. 41 indexed citations

17.

Manning, William C., John E. Murphy, Douglas J. Jolly, Steven J. Mento, & Robert Ralston. (1998). Use of a recombinant murine cytomegalovirus expressing vesicular stomatitis virus G protein to pseudotype retroviral vectors. Journal of Virological Methods. 73(1). 31–39. 10 indexed citations

18.

Zerfass, K., Line M. Levy, Francesca Ciccolini, et al.. (1995). Cell cycle-dependent disruption of E2F-p107 complexes by human papillomavirus type 16 E7. Journal of General Virology. 76(7). 1815–1820. 20 indexed citations

19.

Koziel, Margaret James, Darryll D. Dudley, Johnson T. Wong, et al.. (1992). Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. The Journal of Immunology. 149(10). 3339–3344. 418 indexed citations breakdown →

20.

Ralston, Robert. (1991). Complementation of transforming domains in E1a/myc chimaeras. Nature. 353(6347). 866–868. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact